Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension
Restricted accessOtherFirst published online September, 2009
Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension
Introduction. This subgroup analysis assessed the effects of treatment based on the direct renin inhibitor, aliskiren, or the angiotensin-converting enzyme inhibitor, ramipril, on plasma renin activity (PRA), plasma renin concentration (PRC) and other biomarkers in a 26-week randomised, double-blind trial. Changes in PRA and PRC after stopping treatment were also assessed.
Methods. After placebo run-in, 842 patients (mean sitting diastolic blood pressure (BP) 95—109 mmHg) were randomised to aliskiren 150 mg or ramipril 5 mg. Dose titration and hydrochlorothiazide addition were allowed after Week 6 and 12, respectively, for inadequate BP control. Patients completing active treatment were re-randomised to current regimen or placebo during a 4-week posttreatment phase.
Results. BP reductions were independent of baseline PRA at Week 12, were greater with aliskiren- than ramipril-based therapy at Week 26 (17.9/13.3 vs. 15.2/12.0 mmHg, p<0.05) and persisted for longer after stopping aliskiren. Aliskiren-based therapy reduced geometric mean PRA (−63%, p<0.05; n=103), while ramipril-based therapy increased PRA (+143%, p<0.05; n=100) at Week 26; PRC increased in both groups (aliskiren: +224% [n=33], ramipril: +145% [n=39], both p<0.05). Four weeks after stopping aliskiren-based therapy, PRA remained 52% below pre-treatment baseline; PRA returned to baseline 2 weeks after stopping ramipril-based therapy.
Conclusions. Aliskiren-based therapy produced sustained BP and PRA reductions over 26 weeks; ramipril-based therapy lowered BP and increased PRA. PRA reductions persisted 4 weeks after stopping aliskiren, suggesting an inhibitory effect beyond the elimination half-life of the drug.
Vander AJ, Geelhoed GWInhibition of renin secretion by angiotensin. II. Proc Soc Exp Biol Med1965;120:399-403.
2.
Azizi M., Menard J.Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation2004;109:2492-9.
3.
Hollenberg NK , Fisher ND, Price DAPathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension1998;32:387-92.
4.
Mooser V., Nussberger J., Juillerat L. et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol1990;15:276-82.
5.
van den Meiracker AH, Jan Danser AHAliskiren: the first direct renin inhibitor for hypertension. Curr Cardiol Rep2007;9:470-6.
6.
Oh BH, Mitchell J., Herron JR et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension . J Am Coll Cardiol2007;49:1157-63.
7.
Villamil A., Chrysant SG, Calhoun D. et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens2007;25:217-26.
8.
Pool JL, Gradman AH, Kolloch R. et al. Aliskiren, a novel renin inhibitor, provides long-term suppression of the renin system, when used alone or in combination with hydrochlorothiazide in the treatment of hypertension. Eur Heart J2006;27(suppl):119.
9.
Azizi M., Menard J., Bissery A. et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol2004;15:3126-33.
10.
Oparil S., Yarows SA, Patel S. et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet2007;370:221-9.
11.
Jordan J., Engeli S., Boye SW et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension2007;49:1047-55.
12.
Gradman AH, Flack JM, Arora V. et al. Suppression of the renin system by the novel orally effective direct renin inhibitor aliskiren: a pooled analysis of 1612 patients with hypertension . Circulation2006;114(suppl 18):773.
13.
Uresin Y., Taylor AA, Kilo C. et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension . J Renin Angiotensin Aldosterone Syst2007 ;8:190-8.
14.
Latini R., Masson S., Anand I. et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J2004;25:292-9.
15.
Vergaro G., Fontana M., Poletti R. et al. Plasma renin activity is an independent prognostic factor in chronic heart failure. Eur Heart J2008;29(suppl 1):393.
Andersen K. , Weinberger MH, Egan B. et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens2008;26:589-99.
18.
Yusuf S., Sleight P., Pogue J. et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.N Engl J Med2000;342:145-53.
19.
Gradman AH, Schmieder RE, Lins RL et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients . Circulation2005;111:1012-18.
20.
Lees KRThe dose-response relationship with angiotensin converting enzyme inhibitors: effects on blood pressure and biochemical parameters. J Hypertens1992; 10(suppl):S3-11.
21.
de Leeuw PW , Lugtenburg PL, van Houten H. et al. Preliminary experiences with HOE 498, a novel long-acting converting enzyme inhibitor, in hypertensive patients . J Cardiovasc Pharmacol1985;7:1161-5.
22.
Menard J., Guyene TT, Peyrard S., Azizi M.Conformational changes in prorenin during renin inhibition in vitro and in vivo. J Hypertens2006;24:529-34.
23.
Nussberger J., Gradman AH, Schmieder RE et al. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension . Int J Clin Pract2007;61:1461-8.
24.
Menard J., Azizi M.The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren. J Hypertens2007;25:1775-82.
25.
Danser AH, Charney A., Feldman DL et al. The renin rise with aliskiren: it’s simply stoichiometry . Hypertension2008;51:e27-8.
26.
Feldman DL, Jin L., Xuan H. et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension2008;52:130-6.
27.
Krop M., Garrelds IM, de Bruin RJ et al. Aliskiren accumulates in renin secretory granules and binds plasma prorenin. Hypertension2008;52:1076-83.
28.
Sealey JE, Laragh JHAliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens2007;20:587-97.
29.
Alderman MH , Cohen HW, Sealey JE, Laragh JHPlasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens2004;17:1-7.
30.
Koulouris S. , Symeonides P., Triantafyllou K. et al. Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus. Am J Cardiol2005 ;95:1386-8.
31.
Mitrovic V. , Klein HH, Krekel N. et al. Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis. Z Kardiol2005;94:336-42.
32.
Lopez Santi RG, Valeff EC, Duymovich CR et al. Effects of an angiotensin-converting enzyme inhibitor (ramipril) on inflammatory markers in secondary prevention patients: RAICES Study. Coron Artery Dis2005 ;16:423-9.
33.
Ridker PM, Danielson E., Rifai N., Glynn RJValsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension2006;48:73-9.
34.
Parving HH, Persson F., Lewis JB et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy . N Engl J Med2008;358:2433-46.
35.
Persson F., Rossing P., Schjoedt KJ et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int2008;73:1419-25.
